Research Focus

Strategy and Innovation; Business Intelligence Analyst II

Recent additions – View all

1. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy

   Journal Article

   Morris, P. G.; Abrey, L. E.; Reiner, A. S.; Wu, N.; Panageas, K. S.; Seko, B. S.; Deangelis, L. M.; Omuro, A.
   Leukemia and Lymphoma (2011)

   Fulltext@MSK | Save
2. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)

   Meeting Abstract

   Omuro, A. M.; Beal, K.; Karimi, S.; Chan, T. A.; Panageas, K.; Nayak, L.; Seko, B.; DeAngelis, L. M.; Abrey, L. E.; Gutin, P. H.
   Journal of Clinical Oncology (2010)

   Fulltext@MSK | Save
3. Methotrexate (M) area under the curve (AUC) and creatinine clearance (CrCl) as prognostic factors in primary central nervous system lymphoma (PCNSL)

   Meeting Abstract

   Morris, P. G.; Abrey, L. E.; Reiner, A. S.; Panageas, K.; Seko, B.; DeAngelis, L. M.; Omuro, A. M.
   Journal of Clinical Oncology (2010)

   Fulltext@MSK | Save